{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":4,"podcast":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06567743\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"CORE-008","nct_id":"NCT06567743","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=core-008-nct06567743. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via the current instillation method","label":"Experimental: Cohort A, Arm 1","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort A, Arm 2","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort A, Arm 3","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort B, Arm 1","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method.","label":"Experimental: Cohort B, Arm 2","type":"EXPERIMENTAL"},{"description":"At all treatment visits cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method followed by gemcitabine instilled intravesically","label":"Experimental: Cohort CX, Arm 1","type":"EXPERIMENTAL"},{"description":"Cretostimogene (1 x 1012 vp) will be administered intravesically via an alternative instillation method for two consecutive weeks, followed by gemcitabine administered intravesically in the third week on a cyclic 2:1 visit schedule basis","label":"Experimental: Cohort CX, Arm 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-30","type":"ESTIMATED"},"conditions":["High-Risk Non-Muscle-Invasive Bladder Cancer"],"enrollment":{"count":325,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cretostimogene Grenadenorepvec","otherNames":["CG0070"],"type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"CG Oncology, Inc.","official_title":"A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Cohort A (Arm 1 and 2): Complete response rate","timeFrame":"At 11 and 24 weeks"},{"measure":"Cohort A (Arm 3): High- Grade Event-Free Survival","timeFrame":"48 months"},{"measure":"Cohort B (Arm 1): Complete response rate","timeFrame":"At 11 and 24 weeks"},{"measure":"Cohort B (Arm 2): High-Grade Event-Free Survival","timeFrame":"48 months"},{"measure":"Cohort CX (Arms 1 and 2): High-Grade Event-Free Survival","timeFrame":"48 months"},{"measure":"Cohort CX (Arms 1 and 2): Safety","timeFrame":"48 months"}],"references":[],"start_date":{"date":"2024-09-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","url":"https://clinicaltrials.gov/study/NCT06567743"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/core-008-nct06567743"}